Journal List > J Korean Endocr Soc > v.24(4) > 1003505

TOOLS
The Korean Endocrine Society, The Korean Society of Bone Metabolism, The Korean Society of Osteoporosis, and The Korean Association of Oral and Maxillofacial Surgeons: Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) - Position Statement of Korea -
Review Article
Journal of Korean Endocrine Society

Journal of Korean Endocrine Society 2009; 24(4): 227-230.

Published online: 31 December 2009

DOI: https://doi.org/10.3803/jkes.2009.24.4.227

Bisphosphonate Related Osteonecrosis of the Jaw (BRONJ) - Position Statement of Korea -

The Korean Endocrine SocietyThe Korean Society of Bone MetabolismThe Korean Society of OsteoporosisThe Korean Association of Oral and Maxillofacial Surgeons

Copyright © 2009 Korean Endocrine Society

References

1. Task force on bisphosphonate-related osteonecrosis of the jaws: American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw-2009 Update. 2009. January 15th. Approved by the Board of Trustees http://www.aaoms.org/docs/position_papers/bronj_update.pdf.
2. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007. 22:1479–1491.
3. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003. 61:1115–1118.
4. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004. 62:527–534.
5. Woo SB, Hellstein JW, Kalmar JR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006. 144:753–761.
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007. 356:1809–1822.
7. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008. 139:23–30.
8. Mavrokokki A, Cheng A, Stein B, Goss A. The nature and frequency of bisphosphonates-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007. 65:415–423.
9. Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J. 2008. 101:160–165.
10. Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonate: a critical review. Am J Med. 2009. 122:S33–S45.
TOOLS
Similar articles